Replies to post #208053 on Biotech Values

[rogerm]

The best Alopecia Areata trial result was obtained with oral Ruxolitinib. ACRS appears to be far behind INCY which is running a P2 topical ruxolitinib and CNCE which has a P2 with a oral deuterated ruxolitinib. http://www.investorvillage.com/smbd.asp?mb=18114&mn=596&pt=msg&mid=16391346